PeriRx, LLC, hosts free continuing education event to unveil breakthrough salivary DNA test for oral cancer detection

PeriRx LLC, a premier developer of breakthrough, noninvasive, oral diagnostic technology, will be hosting a free continuing education event in the Philadelphia area to unveil its breakthrough salivary DNA test for early and accurate oral cancer detection on Thursday, November 6, in Havertown, Pennsylvania.

Oct 1st, 2014
Perirxlogo
PeriRx LLC, a premier developer of breakthrough, noninvasive, oral diagnostic technology, will be hosting a free continuing education event in the Philadelphia area to unveil its breakthrough salivary DNA test for early and accurate oral cancer detection.

According to PeriRx CEO and founder Stephen M. Swanick, “During this event, we will fully-explain the science behind SaliMark OSCC, the most clinically advanced molecular DNA biomarker test for oral squamous cell carcinoma detection. Attendees will also learn how to integrate this test into their day-today work flow. In addition, three continuing education credits will be given at the end of the course.”

ADDITIONAL READING |Improving early detection of oral squamous cell carcinoma with advanced salivary diagnostics may impact mortality

Specifically, the CE event which will include peer-to-peer networking, open bar and light fare, will be held on Thursday, November 6, from 5 p.m. to 9 p.m. at the Llanerch Country Club in Havertown, Pennsylvania, which is on the outskirts of Philadelphia.

RELATED |PeriRx LLC’s robust product pipeline includes salivary test for Sjögren’s Syndrome

The CE course faculty consists of Neil R. Gottehrer, DDS, Dental Director, PeriRx, LLC; Jack Martin, MD, board-certified cardiologist, medical director PeriRx, LLC; Stephen M. Swanick, CEO and founder PeriRx, LLC; Theresa Grady, RDH, senior director of hygiene program, Philadelphia Community College.

Online registration is available here: www.PeriRx.com/Invitation

About SaliMark™ OSCC
Development of this simple-to-use, painless, and noninvasive test was based on the strong scientific foundation of NIH-funded research with initial discovery and prevalidation work conducted by Dr. David Wong of the University of California at Los Angeles. The SaliMark OSCC test also has the distinction of being the first of its kind assay in the world to aid in the identification and early detection of oral lesions at the highest risk for cancer. Recently, the Salimark OSCC test underwent a PRoBE (prospective-specimen-collection, retrospective-blinded-evaluation) design study which is the most rigorous biomarker validation available. In addition, PeriRx successfully completed a validation of the mRNA markers at the University of Michigan, Michigan State University and the St. Johns Providence Health System in Detroit.

About PeriRx LLC
Based in Havertown, Pennsylvania, PeriRx LLC is a premier developer of breakthrough, noninvasive, oral diagnostic technology that will help clinical professionals detect and treat diseases sooner and enhance the practice of wellness management.

The company was founded in 2008 to explore, innovate, and develop novel therapeutics or devices focused on the oral inflammatory/systemic connection. The PeriRx executive team consists of CEO Stephen M. Swanick, an entrepreneur and experienced drug and device development professional; Dr. Neil Gottehrer, a practicing dentist; and Dr. Jack Martin, a cardiologist.

PeriRx obtained its patented and patent-pending technologies from inventor Dr. David Wong’s firm RNAmeTRIX and the Regents of the University of California at Los Angeles. PeriRx and RNAmeTrix have ongoing agreements which ensure the continuing research and development necessary to advance product development from clinical trial, through regulatory FDA approval, and into commercialization.

More in Oral Cancer